Tenecteplasum and alteplasum needed by patients with infraction and stroke in hospital will now be manufactured in Russia. This issue was discussed at the Russian Pharmaceutical Forum, where it was announced that NPO Petrovax Pharm on agreement with the German Boehringer Ingelheim this June will start manufacture of the first batches of innovative thrombolytics – Actilyse (alteplasum) and Metalyse (tenecteplasum).
It should be reminded, that NPO Petrovax Pharm is the leading Russian researcher and manufacturer of innovative immunobiological drugs and vaccines well-acknowledged by the Russian pharmaceutical community for over 20 years (the company was founded in 1996). The company operates in full compliance with international standards GMP EU and ISO:9001.
The company is focused on development and manufacture of original innovative drugs, including vaccines for influenza and pneumococcal infection for the National Immunization Schedule, Immunobiological products. Full cycle production sites manufacture pharmaceutical substances, drugs in syringes, ampoules, vials and polymer containers in liquid, soft and solid pharmaceutical forms.